Relatlimab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Relatlimab is a monoclonal antibody designed for the treatment of melanoma.[3][4] It is used in combination with nivolumab to treat melanoma.[2][5]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Lymphocyte activation gene-3 (LAG-3) |
| Clinical data | |
| Other names | BMS-986016, relatlimab-rmbw |
| License data |
|
| Routes of administration | Intravenous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6472H9922N1710O2024S38 |
| Molar mass | 145288.79 g·mol−1 |
Relatlimab is a Lymphocyte activation gene-3 (LAG-3) inhibitor.[2][5] It is under development by Bristol-Myers Squibb.[2][5] It is made using Chinese hamster ovary cells.[2]
History
In 2004, Drew Pardoll and colleagues discovered that the lymphocyte-activation gene 3, or LAG-3, was a new immune checkpoint.[6][7] Checkpoints inhibitors are proteins that stop the immune system from responding to cancer cells. Checkpoint inhibitor drugs block these proteins, unleashing the immune system to battle the cancer.[8]
As stated in the official John Hopkins Technological Ventures Press:[6]
- 2004: Drew Pardoll discovers that LAG-3 is a new immune checkpoint.[9]
- 2010: Pardoll and his research team begin a study to see how relatlimab, a LAG-3 blocking drug, treats cancer in mice.[10]
- 2012: Findings from the study are published showing that a combination of a LAG-3 blocker and PD-1 blocker is an effective cancer treatment.[8]
- 2016: The Join effort including Drew Pardoll, Shirley Liu, Cliff Meyer and Eduardo Gusmao has led to significant advances on the effectiveness as LAG-3 + PD-1 checkpoint blockade immunotherapy.[11]
- 2018: The RELATIVITY-047 trial begins enrolling patients and randomly assigning them to receive relatlimab with nivolumab or nivolumab alone.[12]
- January 2022: Results from the RELATIVITY-047 trial published in The New England Journal of Medicine show the combination treatment with relatlimab to be a more effective treatment than nivolumab alone.[13]
- March 2022: The FDA gives approval for the combination treatment (relatlimab and nivolumab, marketed as Opdualag) as a new therapy for patients with metastatic or inoperable melanoma.[14]
The combination nivolumab/relatlimab (Opdualag) was approved for medical use in the United States in March 2022.[2][5]
Names
Relatlimab is the United States Adopted Name (USAN) and the international nonproprietary name (INN).[15][16][17]
